Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine

Author：                    

Publisher： Spandidos Publications

E-ISSN： 1791-2431|34|1|504-510

ISSN： 1021-335X

Source： Oncology Reports, Vol.34, Iss.1, 2015-01, pp. : 504-510

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model

By        

Oncology Reports, Vol. 30, Iss. 3, 2013-01 ,pp. : 1087-1093

Spandidos Publications

Access to resources Recommend Favorite

Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells

By              

Oncology Reports, Vol. 34, Iss. 6, 2015-01 ,pp. : 2864-2870

Spandidos Publications

Access to resources Recommend Favorite

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

By Valabrega Giorgio  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 29-40

Springer Publishing Company

Access to resources Recommend Favorite

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance

By Dua Rajiv  

Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. : 685-697

Springer Publishing Company

Access to resources Recommend Favorite